FibroGen Reports Fourth Quarter and Full Year 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street dips as higher yields, rising oil prices mark shaky start to SeptemberÂ
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- The Warsh pivot markets didn't expect
FibroGen (FGEN) PT Lowered to $79 at Stifel
February 28, 2018 6:27 AM ESTStifel lowered its price target on FibroGen (NASDAQ: FGEN) to $79.00 (from $80.00) while maintaining a Buy rating following Q4 results.
Analyst Alex Schwartz noted for chronic kidney disease (CKD) anemia with roxadustat, the company now guided topline data in the U.S. during 4Q18 and an NDA filing in 1H19.
... More